{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:46:30Z","timestamp":1791744390497,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03339-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:16:39Z","timestamp":1781064999000},"page":"1868-1876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Verification and optimization of the VTE risk stratification system for multiple myeloma"],"prefix":"10.1007","volume":"59","author":[{"given":"Yuexiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"2","key":"3339_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","volume":"145","author":"C Eby","year":"2009","unstructured":"Eby C (2009) Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 145(2):151\u2013163. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07577.x","journal-title":"Br J Haematol"},{"issue":"9","key":"3339_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood.2020005125","volume":"136","author":"CA Bradbury","year":"2020","unstructured":"Bradbury CA, Craig Z, Cook G et al (2020) Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 136(9):1091\u20131104. https:\/\/doi.org\/10.1182\/blood.2020005125","journal-title":"Blood"},{"issue":"2","key":"3339_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414\u2013423. https:\/\/doi.org\/10.1038\/sj.leu.2405062","journal-title":"Leukemia"},{"issue":"6","key":"3339_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/1076029614521280","volume":"20","author":"MP Crowley","year":"2014","unstructured":"Crowley MP, Eustace JA, O\u2019Shea SI, Gilligan OM (2014) Venous thromboembolism in patients with myeloma: incidence and risk factors in a real-world population. Clin Appl Thromb Hemost 20(6):600\u2013606. https:\/\/doi.org\/10.1177\/1076029614521280","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"3339_CR5","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Pfeiffer RM, Bj\u00f6rkholm M, Schulman S, Landgren O (2012) Thrombosis is associated with inferior survival in multiple myeloma. Haematologica 97(10):1603\u20131607. https:\/\/doi.org\/10.3324\/haematol.2012.064444","journal-title":"Haematologica"},{"issue":"6","key":"3339_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/02683555231176911","volume":"38","author":"Q Liu","year":"2023","unstructured":"Liu Q, Chen L, Wang Z, Peng Z, Chen W, Pan Y, Wang Y, Sha Y (2023) The role of D-dimer and fibrinogen testing in catheter-directed thrombolysis with urokinase for deep venous thrombosis. Phlebology 38(6):389\u2013397. https:\/\/doi.org\/10.1177\/02683555231176911","journal-title":"Phlebology"},{"issue":"1","key":"3339_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.36290\/vnl.2019.009","volume":"65","author":"Z Kr\u00e1l","year":"2019","unstructured":"Kr\u00e1l Z, Adam Z, Folber F, Moulis M, Tom\u00ed\u0161ka M, \u0158\u00edhov\u00e1 L, \u0160tork M, Bulikov\u00e1 A, Pour L, Krej\u010d\u00ed M, Sandeck\u00e1 V, Koukalov\u00e1 R, \u0158eh\u00e1k Z, \u010cerm\u00e1kov\u00e1 Z (2019) Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma. Vnitr Lek 65(1):37\u201344","journal-title":"Vnitr Lek"},{"issue":"2","key":"3339_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.10454","volume":"92","author":"JJ Auwerda","year":"2007","unstructured":"Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW (2007) Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 92(2):279\u2013280. https:\/\/doi.org\/10.3324\/haematol.10454","journal-title":"Haematologica"},{"issue":"6","key":"3339_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF et al (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587\u2013600. https:\/\/doi.org\/10.1200\/JCO.2013.48.7934","journal-title":"J Clin Oncol"},{"issue":"11","key":"3339_CR10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.25603","volume":"94","author":"KM Sanfilippo","year":"2019","unstructured":"Sanfilippo KM, Luo S, Wang TF et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94(11):1176\u20131184. https:\/\/doi.org\/10.1002\/ajh.25603","journal-title":"Am J Hematol"},{"issue":"7","key":"3339_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, Gage BF, Garcia DA, Lyman GH, Sanfilippo KM (2019) Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw 17(7):840\u2013847. https:\/\/doi.org\/10.6004\/jnccn.2018.7273","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"3339_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood.2022015727","volume":"140","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R, Rybicki L, Wei W, Valent J, Faiman BM, Samaras CJ, Anwer F, Khorana AA (2022) Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood 140(23):2443\u20132450. https:\/\/doi.org\/10.1182\/blood.2022015727","journal-title":"Blood"},{"issue":"9","key":"3339_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3760\/cma.j.issn.0253-2727.2022.09.003","volume":"43","author":"Thrombosis","year":"2022","unstructured":"Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, Thrombosis, Group H, Chinese Society of Hematology, Chinese Medical Association (2022) Expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China (2022). Zhonghua Xue Ye Xue Za Zhi 43(9):726\u2013731. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.09.003. Chinese","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"07","key":"3339_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.13201\/j.issn.1004-2806.2024.07.006","volume":"37","author":"M Wang","year":"2024","unstructured":"Wang M, Zhang B, Li Q, Zhao F, Hu Y, Sun CY (2024) Exploring the prevention status of venous thromboembolism in Chinese multiple myeloma based on single-center real-world data and the predictive value of related risk stratification systems. J Clin Hematol 37(07):468\u2013473. https:\/\/doi.org\/10.13201\/j.issn.1004-2806.2024.07.006","journal-title":"J Clin Hematol"},{"issue":"5","key":"3339_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M et al (2023) Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 34(5):452\u2013467. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014","journal-title":"Ann Oncol"},{"issue":"4","key":"3339_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jtha.2025.01.009","volume":"23","author":"C Cox","year":"2025","unstructured":"Cox C, Roberts LN (2025) Basics of diagnosis and treatment of venous thromboembolism. J Thromb Haemost 23(4):1185\u20131202. https:\/\/doi.org\/10.1016\/j.jtha.2025.01.009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3339_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12959-023-00534-y","volume":"21","author":"X Li","year":"2023","unstructured":"Li X, Sun X, Fang B et al (2023) Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma. Thromb J 21(1):105. https:\/\/doi.org\/10.1186\/s12959-023-00534-y","journal-title":"Thromb J"},{"issue":"10","key":"3339_CR18","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.3390\/jcm13102829","volume":"13","author":"HJ Han","year":"2024","unstructured":"Han HJ, Kim M, Lee J, Suh HS (2024) The Risk of Venous Thromboembolism and Ischemic Stroke Stratified by VTE Risk Following Multiple Myeloma: A Korean Population-Based Cohort Study. J Clin Med 13(10):2829. https:\/\/doi.org\/10.3390\/jcm13102829","journal-title":"J Clin Med"},{"issue":"3","key":"3339_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/09537104.2013.805405","volume":"25","author":"D Lemancewicz","year":"2014","unstructured":"Lemancewicz D, Bolkun L, Mantur M, Semeniuk J, Kloczko J, Dzieciol J (2014) Bone marrow megakaryocytes, soluble P-selectin and thrombopoietic cytokines in multiple myeloma patients. Platelets 25(3):181\u2013187. https:\/\/doi.org\/10.3109\/09537104.2013.805405","journal-title":"Platelets"},{"issue":"2","key":"3339_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/bjh.16774","volume":"192","author":"LR O\u2019Sullivan","year":"2021","unstructured":"O\u2019Sullivan LR, Meade-Murphy G, Gilligan OM, Mykytiv V, Young PW, Cahill MR (2021) Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. Br J Haematol 192(2):322\u2013332. https:\/\/doi.org\/10.1111\/bjh.16774","journal-title":"Br J Haematol"},{"issue":"2","key":"3339_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/bjh.19612","volume":"205","author":"YC Chang","year":"2024","unstructured":"Chang YC, Song J, Chi KY, Gao W, Chang Y, Chiang CH, Hsia YP, Chiang CH (2024) The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy. Br J Haematol 205(2):473\u2013477. https:\/\/doi.org\/10.1111\/bjh.19612","journal-title":"Br J Haematol"},{"issue":"22","key":"3339_CR22","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R et al (2023) Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA 329(22):1924\u20131933. https:\/\/doi.org\/10.1001\/jama.2023.7843","journal-title":"JAMA"},{"issue":"3","key":"3339_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.19017","volume":"203","author":"TA Costa","year":"2023","unstructured":"Costa TA, Felix N, Costa BA, Godoi A, Nogueira A, Rossi A (2023) Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis. Br J Haematol 203(3):395\u2013403. https:\/\/doi.org\/10.1111\/bjh.19017","journal-title":"Br J Haematol"},{"issue":"4","key":"3339_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjh.16653","volume":"190","author":"RF Cornell","year":"2020","unstructured":"Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G (2020) Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 190(4):555\u2013561. https:\/\/doi.org\/10.1111\/bjh.16653","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03339-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:37:04Z","timestamp":1791743824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03339-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03339-8","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}